Scholarlink

Purpose <p>To assess the incidence, clinical characteristics, and post-progression management strategy of resistance to immunotherapy–chemotherapy combination in unresectable biliary tract carcinoma (uBTC).</p> Experimental Design <p>Patients with uBTC from multiple centers who received immunotherapy–chemotherapy combination were retrospectively included. Baseline characteristics, treatments, pattern of progression, and posttreatment managements were recorded. The primary endpoint was post-progression survival (PPS).</p> Results <p>Out of 194 patients, 130 (67.0%) developed resistance, including 78 (40.2%) with acquired resistance (AR) and 52 (26.8%) with primary resistance (PR). Normal CA19-9 level and combining target therapy were more common in patients with AR. Patients with both AR and PR commonly experience deterioration in general condition and systemic progression. Patients with AR and PR showed no difference in patterns of progression or current post-progression management strategies. A total of 103 (79.2%) patients receiving post-resistance antitumor treatments showed improved prognosis than those receiving best supportive care, while patients with AR received additional survival benefit than those with PR. Changing immunotherapy regimen after resistance brings significant survival benefit in patients with AR (mPPS: 15.1 vs. 9.50 months, HR = 0.41), but not those with PR. Adding/switching target therapy regimens (HR = 0.39) and local regional therapies (LRT) (HR = 0.36) after resistance brings potential benefit in patients with PR.</p> Conclusions <p>Changing immunotherapy regimen is a promising strategy for overcoming AR to first-line immunotherapy–chemotherapy combination in uBTC, while adjusting targeted therapy and adding LRT may help overcome PR.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月29日

查看全文
  • Xiangqi Chen,
  • Zixiang Zhou,
  • Shuofeng Li,
  • Guanhua Yu,
  • Shi Feng,
  • Ze Zhou,
  • Boyu Sun,
  • Shanshan Wang,
  • Kai Liu,
  • Chengjie Li,
  • Mingjian Piao,
  • Mingming Wang,
  • Yihong Zhang,
  • Hu Li,
  • Chengpei Zhu,
  • Zhenyu Zhu,
  • Haitao Zhao

摘要

Purpose

To assess the incidence, clinical characteristics, and post-progression management strategy of resistance to immunotherapy–chemotherapy combination in unresectable biliary tract carcinoma (uBTC).

Experimental Design

Patients with uBTC from multiple centers who received immunotherapy–chemotherapy combination were retrospectively included. Baseline characteristics, treatments, pattern of progression, and posttreatment managements were recorded. The primary endpoint was post-progression survival (PPS).

Results

Out of 194 patients, 130 (67.0%) developed resistance, including 78 (40.2%) with acquired resistance (AR) and 52 (26.8%) with primary resistance (PR). Normal CA19-9 level and combining target therapy were more common in patients with AR. Patients with both AR and PR commonly experience deterioration in general condition and systemic progression. Patients with AR and PR showed no difference in patterns of progression or current post-progression management strategies. A total of 103 (79.2%) patients receiving post-resistance antitumor treatments showed improved prognosis than those receiving best supportive care, while patients with AR received additional survival benefit than those with PR. Changing immunotherapy regimen after resistance brings significant survival benefit in patients with AR (mPPS: 15.1 vs. 9.50 months, HR = 0.41), but not those with PR. Adding/switching target therapy regimens (HR = 0.39) and local regional therapies (LRT) (HR = 0.36) after resistance brings potential benefit in patients with PR.

Conclusions

Changing immunotherapy regimen is a promising strategy for overcoming AR to first-line immunotherapy–chemotherapy combination in uBTC, while adjusting targeted therapy and adding LRT may help overcome PR.